Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
50 Northern Avenue
Boston, MA 02210
Phone: (617) 341-6100Website: https://www.vrtx.com/Careers: www.vrtx.com/careersPatient Assistance Program: www.vrtx.com/medicines/patient-support
Latest news
- Vertex Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy
June 1, 2026 - Vertex Announces US FDA Approval for Label Extensions of Alyftrek and Trikafta, Expanding Availability of These Medicines to ~95% of All People With CF in the United States
April 1, 2026 - Vertex Announces Positive Week 36 Interim Analysis Results for Primary and All Secondary Endpoints in the RAINIER Phase 3 Trial of Povetacicept in Adults With IgA Nephropathy
March 9, 2026 - FDA Approves Journavx (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain
January 30, 2025 - FDA Approves Alyftrek (vanzacaftor/tezacaftor/deutivacaftor) for the Treatment of Cystic Fibrosis
December 20, 2024 - Vertex Announces U.S. FDA Approval for Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non-F508del Trikafta-Responsive Variants
December 20, 2024 - Vertex Announces Results From Phase 2 Study of Suzetrigine for the Treatment of Painful Lumbosacral Radiculopathy
December 19, 2024 - Vertex Announces FDA Acceptance of New Drug Application for Suzetrigine for the Treatment of Moderate-to-Severe Acute Pain
July 30, 2024 - Vertex Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-In-Class Triple Combination Treatment for Cystic Fibrosis
July 2, 2024 - Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain
April 18, 2024
Drugs Associated with Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated manufactures, markets and/or distributes more than 7 drugs in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.
| Brand/Generic Name | Reviews | Rating |
|---|---|---|
|
Alyftrek
Generic name: deutivacaftor/tezacaftor/vanzacaftor Drug class: CFTR combinations |
||
|
Casgevy
Generic name: exagamglogene autotemcel Drug class: miscellaneous uncategorized agents |
||
|
Journavx
Generic name: suzetrigine Drug class: miscellaneous analgesics |
2 reviews | 6.5 / 10 |
|
Kalydeco
Generic name: ivacaftor Drug class: CFTR potentiators |
1 review | 10 / 10 |
|
Orkambi
Generic name: ivacaftor/lumacaftor Drug class: CFTR combinations |
||
|
Symdeko
Generic name: ivacaftor/tezacaftor Drug class: CFTR combinations |
||
|
Trikafta
Generic name: elexacaftor/ivacaftor/tezacaftor Drug class: CFTR combinations |
1 review | 9.5 / 10 |
| For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective). | ||